Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Outperform Rating and 6 Price Target for Geron NASDAQ GERN

Elaine Mendonca by Elaine Mendonca
March 15, 2024
in Breaking News
0
Finance_ stocks to buy
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Wedbush analyst Robert Driscoll has once again expressed confidence in Geron (NASDAQ: GERN), reiterating an Outperform rating and a $6 price target on March 15, 2024. This reaffirmation underscores Wedbush’s optimistic view on Geron’s potential performance, signaling a positive outlook for the stock moving forward.

Geron Corporation (GERN) Stock Skyrockets 82.29% on March 15, 2024: Potential for Growth and Investor Interest

On March 15, 2024, Geron Corporation (GERN) had an impressive performance in the stock market. The stock opened at $3.01, which was $1.26 higher than its previous close. Throughout the day, GERN shares continued to climb, closing at $4.45. This marked a significant increase of $1.44, or 82.29%, from the previous day’s closing price. Investors may have been drawn to GERN on this day due to its strong price momentum and significant price increase. The stock’s performance on March 15th demonstrated that it had the potential for growth and was attracting interest from traders. Investors and analysts may continue to monitor GERN’s performance in the coming days to see if this positive trend continues.

GERN Corporation (GERN) Sees Decrease in Revenue and Net Income, Slight Increase in EPS – March 15, 2024 Update

On March 15, 2024, Geron Corporation (GERN) saw a significant decrease in its total revenue compared to both the previous year and the last quarter. According to data from CNN Money, the total revenue for GERN was $237.00K in the past year, which decreased by 60.23% from the previous year. In the last quarter, the total revenue further decreased to $23.00K, representing an 85.98% decrease from the previous quarter.

The net income for GERN also experienced a decline, with a net loss of -$184.13M in the past year and a net loss of -$51.97M in the last quarter. This represents a 29.76% decrease in net income since the previous year and a 16.0% decrease since the last quarter.

Despite these declines, there was a slight increase in earnings per share (EPS) for GERN. The EPS was -$0.32 in the past year, which increased by 13.39% compared to the previous year. In the last quarter, the EPS remained steady at -$0.09, showing no change from the previous quarter.

Overall, GERN’s stock performance on March 15, 2024, reflected a decrease in total revenue and net income, but a slight increase in earnings per share. Investors will need to closely monitor GERN’s financial performance in the coming quarters.

Tags: GERN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Renewable energy

CBAK Energy Technology Reports Strong Revenue Growth in Q4 2023

Financing and finances

Analysis of Recent Analyst Ratings and Price Targets for APA

Analyzing Acurx Pharmaceuticals A Look at Past Performance and Future Expectations

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com